

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

ARTICLE (starts on next page)

PPI Interactions with Clopidogrel p 2

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 51 (Issue 1303)
January 12, 2009

www.medicalletter.org

PPI Interactions with Clopidogrel

Clopidogrel (*Plavix*), which prevents arterial thrombosis by inhibiting platelet activation, is commonly prescribed (usually with aspirin) for months after acute coronary syndromes and stent implantation.¹ It may also, however, increase the risk of bleeding.² Therefore, a proton pump inhibitor (PPI) such as omeprazole (*Prilosec*, and others) is often given concurrently to decrease the risk of gastrointestinal (GI) bleeding.² Some reports have suggested that omeprazole may interfere with the antiplatelet effect of clopidogrel.

PHARMACOKINETICS — Clopidogrel is a prodrug that is activated by CYP450 enzymes in the liver, principally (it is thought) by CYP2C19. Omeprazole is a strong inhibitor of CYP2C19, but all PPIs may inhibit CYP2C19 to some extent.³ Patients who are carriers of CYP2C19 loss-of-function polymorphisms (common in East Asians) show a marked decrease in platelet responsiveness to clopidogrel.⁴

AN EX VIVO STUDY — A randomized, double-blind study in 124 patients taking aspirin-clopidogrel antiplatelet therapy after coronary stent implantation compared the effects of omeprazole or placebo on the

ability of clopidogrel to inhibit platelet activation in blood samples from the patients. After 7 days of use, omeprazole decreased the antiplatelet effect of clopidogrel.⁵ A similar study found no such interaction between esomeprazole or pantoprazole and clopidogrel.⁶

CLINICAL STUDIES — In a retrospective cohort study using an administrative claims database and published only as a letter to the editor, the Aetna Insurance Company compared myocardial infarction (MI) rates in members receiving clopidogrel with or without a PPI for one year. MIs occurred in 1.38% (66/4800) with clopidogrel alone, in 3.08% (22/712) with “low” PPI exposure, and in 5.03% with “high” PPI exposure (not defined). Among the subset of patients who had significant risk factors such as hypertension or diabetes, MIs occurred in 2.6% (10/384) on clopidogrel alone, 10.0% (9/90) with low PPI exposure, and 11.4% (61/536) with high PPI exposure. The high PPI exposure group had a greater number of patients with pre-existing hypertension and diabetes. Which PPIs were used was not specified.⁷

A retrospective cohort study, published only as an abstract, of more than 14,000 patients who took clopidogrel for 1 year after stent placement (and were at least

Table 1. Proton Pump Inhibitors for Peptic Ulcers/GERD

Drug	Dosage ¹	Tablet/Capsule Size	Cost ²
Esomeprazole — <i>Nexium</i> (AstraZeneca)	20-40 mg once daily	20, 40 mg caps ³	\$172.80
Lansoprazole — <i>Prevacid</i> (TAP)	15-30 mg once daily ⁴	15, 30 mg tabs, ODT	156.30
Omeprazole — generic	20-40 mg once daily ⁴	10, 20, 40 mg caps	92.10
<i>Prilosec</i> (AstraZeneca)			141.90
<i>Prilosec OTC</i>		20 mg tabs	26.99 ⁵
generic			21.99 ⁵
<i>Zegerid</i>		20, 40 mg caps ^{3,6}	150.60
Pantoprazole — generic	20-40 mg once daily	20, 40 mg tabs	112.50
<i>Protonix</i> (Wyeth)			133.80
Rabeprazole — <i>Aciphex</i> (Janssen)	20 mg once daily	20 mg tabs	179.70

OTC = Over the counter; ODT = orally disintegrating tabs.

1. The lower end of the range is generally used for initial treatment of GERD. Customary doses of antisecretory drugs may not be effective in patients with peptic ulcers due to hypersecretory states like Zollinger-Ellison Syndrome.

2. Cost for 30 days' treatment at the lowest dosage, according to the most recent data (November 30, 2008) from retail pharmacies nationwide available from Wolter's Kluwer Health.

3. Also available as an oral suspension, syrup or solution.

4. Lower dose is for GERD and duodenal ulcer; higher dose is for gastric ulcer.

5. Cost of a box of 42 tablets from drugstore.com (accessed December 19, 2008).

6. Both strengths contain sodium bicarbonate 1.1 g; therefore, two 20-mg caps are not equivalent to a 40-mg cap.

80% adherent) compared the incidence of major cardiovascular events in those who took clopidogrel alone (n >9000) with those who also took a PPI (n >4000). Patients taking both drugs had more cardiovascular risk factors and more major cardiovascular events.⁸

A sub-set analysis, also published only as an abstract, of an earlier study (CREDO) that compared clopidogrel with placebo for 1 year after stenting found that patients randomized to clopidogrel who also received a PPI at the discretion of their physician had a higher incidence of cardiovascular events after 1 year compared to those not receiving a PPI, but the same was true of those randomized to placebo.⁹

A prospective, randomized, placebo-controlled trial (COGENT) of clopidogrel plus omeprazole is in progress.

CONCLUSION — Whether omeprazole or other PPIs could interfere with the antiplatelet effect of clopidogrel enough to increase the incidence of cardiovascular events after coronary stenting is unclear. The increased incidence of such events reported retrospectively could also reflect increased risk factors among PPI users. Patients taking both drugs concurrently should probably continue to do so until more data become available.

1. Antiplatelet and anticoagulant drugs. *Treat Guidel Med Lett* 2008; 6:29.
2. DL Bhatt et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 2008; 52:1502.
3. XQ Li, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. *Drug Metab Dispos* 2004; 32:821.
4. J-S Hulot et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. *Blood* 2006; 108:2244.
5. M Gilard et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. *J Am Coll Cardiol* 2008; 51:256.
6. JM Siller-Matula et al. Effects of pantoprazole and esomeprazole on platelet inhibitions by clopidogrel. *Am Heart J* 2009; 157:148.
7. E Pezalla et al. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. *J Am Coll Cardiol* 2008; 52:1038.
8. RE Aubert et al. Understanding variability in antiplatelet drug effects in acute coronary syndromes. Abstract 3998: proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study. *Circulation* 2008; 118:S_815.
9. SP Dunn et al. Understanding variability in antiplatelet drug effects in acute coronary syndromes. Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. *Circulation* 2008; 118:S_815.

The Medical Letter®

On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., Weill Medical College of Cornell University
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D., Blaine M. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.
CONTRIBUTING EDITORS:
 Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
 Eric J. Epstein, M.D. Albert Einstein College of Medicine
 Sandip K. Mukherjee, M.D. F.A.C.C., Yale School of Medicine
ADVISORY BOARD:
 Jules Hirsch, M.D., Rockefeller University
 David N. Juurlink, BPhm, M.D., PhD, Sunnybrook Health Sciences Centre
 Richard B. Kim, M.D., University of Western Ontario
 Gerald L. Mandell, M.D., University of Virginia School of Medicine
 Hans Meinertz, M.D., University Hospital, Copenhagen
 Dan M. Roden, M.D., Vanderbilt University School of Medicine
 F. Estelle R. Simons, M.D., University of Manitoba
 Neal H. Steigbigel, M.D., New York University School of Medicine
SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard
ASSOCIATE EDITOR: Cynthia Macapagal Covey
EDITORIAL FELLOW: Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW: Manouchkathe Cassagnol, Pharm.D., St. John's University
MANAGING EDITOR: Susie Wong
ASSISTANT MANAGING EDITOR: Liz Donohue
PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona
FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski
DIRECTOR OF MARKETING & COMMUNICATIONS: Joanne F. Valentino
VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy
 Founded in 1959 by
 Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address: The Medical Letter, Inc. 1000 Main Street New Rochelle, NY 10801-7537	Subscriptions (US): 1 year - \$98; 2 years - \$167; 3 years - \$235. \$49.00 per year for students, interns, residents and fellows in the US and Canada. CME: \$59 for 26 credits.
Customer Service: Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733 Web Site: www.medicalletter.org E-mail: custserv@medicalletter.org	E-mail site license inquiries to: info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.
Permissions: To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org	

Copyright 2009. ISSN 1523-2859